Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN trial of host thromboinflammatory modulation in hospitalized COVID-19
2020-001739-28Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aprotinin, anakinra, enoxaparin and nadroparin in coronavirus disease 2019 (COVID-19) and Respiratory viral illness (5 arms), sponsored by UZ Leuven. Primary endpoint: Pilot phase of DAWN-ANTICO. Started Apr 2020; status: completed.
02
Drugs
aprotininanakinraenoxaparinnadroparin
03
Conditions
coronavirus disease 2019 (COVID-19)Respiratory viral illness
Beyond the preview
Go deeper on 2020-001739-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001739-28.